TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31476897

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) and percutaneous coronary intervention
Number of subjects: 1660

Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR) and coronary artery bypass grafting
Number of subjects: 1660

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 1660

Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 1660
Study: 28087146

Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 1754

Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 1754
Study: 25686520

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents
Number of subjects: 207

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 207
Study: 24043284

Group type: EXPERIMENTAL
Intervention: Synbiotics (Bifidobacterium lactis plus inulin) added to breast milk or mixed feeding
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (breast milk or mixed feeding)
Number of subjects: 100
Study: 21170802

Group type: EXPERIMENTAL
Intervention: Taekwondo training (50 min a day, 2 days per week for 12 weeks)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 31
Study: 18974654

Group type: EXPERIMENTAL
Intervention: Multidisciplinary predialysis care (MDC)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Conventional or no nephrologist-based care
Number of subjects: 151
Study: 20850296

Group type: EXPERIMENTAL
Intervention: Primary debulking surgery followed by chemotherapy
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Interval debulking surgery
Number of subjects: 479

Group type: COMPARATOR
Intervention: Overall quality of pathology reports
Number of subjects: 479
Study: 16518708

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 1000 mg extended-release once-daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg immediate-release twice-daily
Number of subjects: 19
Study: 12131610

Group type: EXPERIMENTAL
Intervention: Educational booklets
Number of subjects: 59

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Educational booklets (newly diagnosed or less informed patients)
Number of subjects: 59
Study: 9611155

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7798614

Group type: EXPERIMENTAL
Intervention: 0.1% retinoic acid (RA) applied once a day for 4 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RA-treated Langerhans cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RA treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anti-CD11c antibody
Number of subjects: 0
Study: 3044666

Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemic, euglycaemic clamp
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo clamp (0.9% NaCl)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemic, euglycaemic clamp in diabetic subjects
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemic, euglycaemic clamp in one diabetic subject
Number of subjects: 12
Study: 11961625

Group type: EXPERIMENTAL
Intervention: Instrument Positioner (PASSIST)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Instrument Positioner (AESOP)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Surgical Assistant (Control)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Questionnaire on difficulties and comfort of use
Number of subjects: 78
Study: 31173138

Group type: EXPERIMENTAL
Intervention: Endoscopic Transnasal Trans-Sphenoidal Surgery (ETSS)
Number of subjects: 187
Study: 28984041

Group type: EXPERIMENTAL
Intervention: liraglutide 0.9 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: additional OAD
Number of subjects: 0
Study: 27289127

Group type: EXPERIMENTAL
Intervention: Personalized model predictive control (MPC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Proportional integral derivative (PID)
Number of subjects: 20
Study: 24781571

Group type: EXPERIMENTAL
Intervention: Subcutaneous saline injection to increase arterial depth from <2 mm to 2-4 mm
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Subcutaneous arterial depth of 2-4 mm
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study: 22573126

Group type: EXPERIMENTAL
Intervention: Acarbose treatment
Number of subjects: 1368

Group type: COMPARATOR
Intervention: Control group (normotensive individuals at baseline)
Number of subjects: 1368

Group type: EXPERIMENTAL
Intervention: Abdominal obesity at baseline
Number of subjects: 1368

Group type: EXPERIMENTAL
Intervention: Worsening of glucose tolerance
Number of subjects: 1368
Study: 20227301

Group type: EXPERIMENTAL
Intervention: Sildenafil at 40 mg 3 times daily
Number of subjects: 18
Study: 19326341

Group type: COMPARATOR
Intervention: Double-dose antioxidant supplement
Number of subjects: 60

Group type: COMPARATOR
Intervention: Gamma-tocopherol (5 and 50 microM for 23 hours)
Number of subjects: 60
Study: 16055637

Group type: EXPERIMENTAL
Intervention: Consensus expressed by descriptive adjectives (large vs. small)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Large sources
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Small minority
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consensus expressed in terms of descriptive adjectives (large, small)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consensus expressed in terms of percentages (82%, 18%, 52%, 48%)
Number of subjects: 0
Study: 12376522

Group type: EXPERIMENTAL
Intervention: Mouthwash (swish)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cytobrush
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Mouthwash
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cytobrush with variations (rubbing cheeks, morning collection)
Number of subjects: 22
Study: 10197402

Group type: EXPERIMENTAL
Intervention: Standard ignoring treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Graduated ignoring treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study: 8530300

Group type: EXPERIMENTAL
Intervention: Diets relatively high in non-starch polysaccharide (NSP)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Low fat diets
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group (remainder of the sample)
Number of subjects: 136
Study: 2132137

Group type: EXPERIMENTAL
Intervention: Bretylium 10 mg/kg
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Lidocaine 2 mg/kg
Number of subjects: 33

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 33
Study: 358527

Group type: EXPERIMENTAL
Intervention: Oxybutynin chloride 10 mg
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Oxybutynin chloride 20 mg
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 31220505

Group type: EXPERIMENTAL
Intervention: Combined exercise protocol (aerobic and resistance training)
Number of subjects: 32
Study: 28778550

Group type: EXPERIMENTAL
Intervention: Carbohydrate‐electrolyte solution (CE)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Carbohydrate‐electrolyte‐protein solution (CEP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Distilled water (DW)
Number of subjects: 12
Study: 26032216

Group type: EXPERIMENTAL
Intervention: Electrically induced muscle cramps (EIMCs) applied twice a week, 3x6 EIMCs of 5 seconds each
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (nCP) with ankle fixed at 0° plantar flexion
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (nCP)
Number of subjects: 15
Study: 22788697

Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment applied to affected nails for 12 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (untreated nails on the other hand)
Number of subjects: 21
Study: 21775557

Group type: EXPERIMENTAL
Intervention: Leucine-enriched essential amino acids (L-EAA) - 10 g EAA with 3.5 g leucine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Essential amino acids (EAA) - 10 g EAA with 1.87 g leucine
Number of subjects: 8
Study: 19627358

Group type: EXPERIMENTAL
Intervention: XP Bond/CoreXFlow + DT Light‐Post
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Panavia F 2.0 + Tech 21
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: RelyX Unicem + RelyX
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control specimens (stored in artificial saliva)
Number of subjects: 84
Study: 17108753

Group type: EXPERIMENTAL
Intervention: Web-based intervention
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Printed material intervention
Number of subjects: 73

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 73
Study: 12745494

Group type: EXPERIMENTAL
Intervention: Hospitalization as a teachable moment for quitting
Number of subjects: 2350

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 2350

Group type: EXPERIMENTAL
Intervention: Stage of change
Number of subjects: 2350

Group type: EXPERIMENTAL
Intervention: Time to first cigarette
Number of subjects: 2350
Study: 10964636

Group type: EXPERIMENTAL
Intervention: ER tie-in
Number of subjects: 458

Group type: COMPARATOR
Intervention: No tie-in
Number of subjects: 458
Study: 8783540

Group type: EXPERIMENTAL
Intervention: Saline alone for maintenance of peripheral intravenous access devices
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heparinized saline for maintenance of peripheral intravenous access devices
Number of subjects: 0
Study: 1619996

Group type: EXPERIMENTAL
Intervention: Chromium supplementation (250 micrograms of chromium orally as chromium chloride)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 6714820

Group type: EXPERIMENTAL
Intervention: Orgotein (Superoxide Dismutase)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Corticosteroid (Corticoid)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both treatments (Orgotein and Corticoid)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Joint diameter, strength of pinch-grip, range of motion
Number of subjects: 31
Study: 30777080

Group type: EXPERIMENTAL
Intervention: Performance review and facilitated feedback intervention
Number of subjects: 108

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 108
Study: 30064991

Group type: EXPERIMENTAL
Intervention: GM-CSF (3 μg/kg/day), subcutaneous, once daily for 4 days
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 38
Study: 26867541

Group type: EXPERIMENTAL
Intervention: Blood flow restricted exercise (BFR exercise group)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard exercise (control exercise group)
Number of subjects: 32
Study: 24579075

Group type: EXPERIMENTAL
Intervention: Probiotic treatment (Lactobacillus acidophilus, Lactobacillus delbrueckii subsp. bulgaricus, and Bifidobacterium bifidus)
Number of subjects: 43
Study: 22514718

Group type: EXPERIMENTAL
Intervention: Non-pharmaceutical interventions (NPIs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collection of respiratory specimens from individuals reporting ARI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collection of specimens only from individuals reporting febrile ARI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collection and testing of sera before and after influenza activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RT-PCR testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Routine collection of specimens for RT-PCR testing
Number of subjects: 0
Study: 20110153

Group type: EXPERIMENTAL
Intervention: Alfimeprase (0.3 mg/kg)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Intrathrombus placebo (IT)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Perithrombus placebo (PT)
Number of subjects: 402
Study: 18051617

Group type: EXPERIMENTAL
Intervention: Triple P-group training
Number of subjects: 280
Study: 16076989

Group type: EXPERIMENTAL
Intervention: Green tea‐caffeine mixture (270 mg epigallocatechin gallate + 150 mg caffeine per day)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Green tea‐caffeine mixture
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: High caffeine consumers
Number of subjects: 76
Study: 12399201

Group type: EXPERIMENTAL
Intervention: 0.6 micro g of purified non‐adsorbed hepatitis B surface antigen (HBsAg)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 3.5 micro g of purified non‐adsorbed hepatitis B surface antigen (HBsAg)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 10 micro g of purified non‐adsorbed hepatitis B surface antigen (HBsAg)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 20 micro g of purified non‐adsorbed hepatitis B surface antigen (HBsAg)
Number of subjects: 64
Study: 9602578

Group type: EXPERIMENTAL
Intervention: Active warming using forced air for 30 min before induction of general anaesthesia and during anaesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Passive protection against heat loss (circulating water mattresses, blankets, fluid warming devices)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Active warming
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 7746026

Group type: EXPERIMENTAL
Intervention: Eferox 100 tablets (100 micrograms levothyroxine‐Na)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference preparation (100 micrograms levothyroxine‐Na)
Number of subjects: 24
Study: 2646206

Group type: EXPERIMENTAL
Intervention: Roxithromycin 300 mg once a day
Number of subjects: 281

Group type: COMPARATOR
Intervention: Erythromycin 500 mg twice a day
Number of subjects: 281
Study: 1215859

Group type: EXPERIMENTAL
Intervention: tetracycline HCl 1 g
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: tetracycline HCl + terpenes 100 mg
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: minocycline 200 mg
Number of subjects: 41

Group type: COMPARATOR
Intervention: cotrimoxazole (sulfamethoxazole 1.6 g + trimethoprim 320 mg)
Number of subjects: 41
Study: 31868987

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham-acupuncture
Number of subjects: 44
Study: 31763286

Group type: COMPARATOR
Intervention: Manual extraction of maggots after instillation of chloroform and turpentine oil mixture
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Oral Ivermectin (6 mg each, two doses 24 hours apart)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Endoscopic clearance of maggots at 24 hours
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Endoscopic clearance of maggots at 48 hours
Number of subjects: 80
Study: 29333775

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1.0 μg·kg⁻¹ bolus, saline diluted to 10 mL, followed by maintenance dose of 0.1-0.4 mL·(kg·h)⁻¹ until 45 min before the end of operation)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal saline (10 mL bolus, followed by maintenance dose of 0.1-0.4 mL·(kg·h)⁻¹ until 45 min before the end of operation)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 80
Study: 26070865

Group type: EXPERIMENTAL
Intervention: NaCl 0.9% (Group A)
Number of subjects: 233

Group type: COMPARATOR
Intervention: NaCl 0.45% (Group B)
Number of subjects: 233
Study: 24973546

Group type: EXPERIMENTAL
Intervention: Clinic-based intervention program (CBIP)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Home-based intervention program (HBIP)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 178
Study: 23052222

Group type: EXPERIMENTAL
Intervention: 600,000 IU vitamin D3
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 300,000 IU vitamin D3
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 100,000 IU vitamin D3
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no vitamin D3)
Number of subjects: 37
Study: 19573672

Group type: EXPERIMENTAL
Intervention: Skin adhesive (2-octylcyanoacrylate)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Subcuticular suture
Number of subjects: 134
Study: 17312205

Group type: EXPERIMENTAL
Intervention: Auricular electroacupuncture (AE) with electrical stimulation, n = 76
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (AA) without electrical stimulation, n = 37
Number of subjects: 149

Group type: COMPARATOR
Intervention: Sham auricular electroacupuncture (NN) with no electrical stimulation, n = 36
Number of subjects: 149
Study: 15498605

Group type: EXPERIMENTAL
Intervention: MSL-109 15 mg
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: MSL-109 60 mg
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 11430552

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) 0.25 mg/kg body weight (ICG1)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) 0.25 mg/kg body weight (ICG2)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Human albumin 20% 1.75 ml/kg body weight (Group ALB)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Hydroxyethyl starch 6% 5.25 ml/kg body weight (Group HAES)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Polygelatine 3.5% 7.0 ml/kg body weight (Group HAEM)
Number of subjects: 31
Study: 9663222

Group type: EXPERIMENTAL
Intervention: 16 interrupted 10-0 nylon sutures
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 2 running 10-0 nylon sutures, each with 8 bites
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 2 running 10-0 nylon sutures, each with 12 bites
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 2 running 10-0 nylon sutures, each with 16 bites
Number of subjects: 62
Study: 7818586

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice a day for 4 weeks
Number of subjects: 652

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 652
Study: 3337412

Group type: COMPARATOR
Intervention: Control (no activated charcoal)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: One-dose activated charcoal (50 g)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Two-dose activated charcoal (50 g)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Three-dose activated charcoal (50 g)
Number of subjects: 13
Study: 2048658

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous fentanyl
Number of subjects: 20
Study: 788767

Group type: EXPERIMENTAL
Intervention: Clomocycline (Megaclor) for 3 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clomocycline over long periods
Number of subjects: 60
Study: 31409363

Group type: EXPERIMENTAL
Intervention: Food bar (FB) containing 20g of whey protein, 25g of isomalto-oligosaccharides, and 7g of fat
Number of subjects: 12

Group type: COMPARATOR
Intervention: Carbohydrate matched dextrose comparator (CHO)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Food bar (FB)
Number of subjects: 12
Study: 28512998

Group type: EXPERIMENTAL
Intervention: Group-based learning collaborative intervention for TTT adherence over 9 months
Number of subjects: 641

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 641
Study: 26429049

Group type: EXPERIMENTAL
Intervention: Laparoscopy combined with transanal endoscopic microsurgery (LT group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Laparoscopic surgery (LA group)
Number of subjects: 60
Study: 23986778

Group type: EXPERIMENTAL
Intervention: High Protein (HP) diet
Number of subjects: 60

Group type: COMPARATOR
Intervention: Energy-restricted control diet
Number of subjects: 60
Study: 21173495

Group type: EXPERIMENTAL
Intervention: Waon therapy (daily for 4 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (standard optimal medications for CHF)
Number of subjects: 40
Study: 19889188

Group type: EXPERIMENTAL
Intervention: ECG lead aVR
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Changes in aVR
Number of subjects: 136
Study: 17324689

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonpharmacological management
Number of subjects: 0
Study: 15070944

Group type: EXPERIMENTAL
Intervention: Long-acting pegylated recombinant leptin (PEG-OB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weight loss
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight loss with PEG-OB treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PEG-OB treatment
Number of subjects: 0
Study: 11240978

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Number of subjects: 52

Group type: COMPARATOR
Intervention: Azathioprine (Control)
Number of subjects: 52
Study: 9492731

Group type: EXPERIMENTAL
Intervention: Metronidazole (500 mg intravenous infusion before operation and again 8 hours later)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Total population (metronidazole + placebo)
Number of subjects: 258
Study: 7810383

Group type: EXPERIMENTAL
Intervention: Maloprim (dapsone/pyrimethamine)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study: 3128132

Group type: EXPERIMENTAL
Intervention: Nitroglycerin infusion, 1 to 2 micrograms.kg‐1.min‐1
Number of subjects: 22

Group type: COMPARATOR
Intervention: No nitroglycerin infusion
Number of subjects: 22
Study: 27778088

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 73

Group type: COMPARATOR
Intervention: Formula feeding
Number of subjects: 73
Study: 27130167

Group type: EXPERIMENTAL
Intervention: Hospital Episode Statistics (HES) data using NHS reference costs
Number of subjects: 292

Group type: COMPARATOR
Intervention: Medical record data
Number of subjects: 292
Study: 25919389

Group type: EXPERIMENTAL
Intervention: Internal thoracic impedance (ITI) monitoring using RS‐207 monitor
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no pleural effusion)
Number of subjects: 100